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Next-generation sequencing
New technologies in DNA and RNA 
sequencing have drastically reduced 
both the cost and the time taken to 
sequence whole human genomes.
Testing for biomarkers
For screening and diagnostics assays, 
miniaturisation engineering can create 
virtual laboratories in a plastic wafer. 
These point-of-care tests will eventually 
supersede traditional ‘brick & mortar’ 
labs.
THE CHALLENGES
Technological developments are driving a shift away from basic diagnosis of established sickness, towards 
a paradigm of defining the lifetime health risks of individuals at birth. What are these developments, and 
how can UCLH Pathology departments adapt to this huge change, embrace the new technological 
advances, and yet still maintain current quality of service?
The consequences...
•Detailed screening of populations
•Identification of ‘disease signatures’
•Delivery of personalised medicine
•Targeting of preventative measures
•Staged therapeutic interventions
•Large cost savings to the NHS.
 
 
Leadership elements
• Reach outside ‘Circle of Influence’ (i.e. 
find an existing agenda to hijack)
• Seek to work with a good manager, and 
agree an ‘end-in-mind’  (Covey)
•Use this platform to promote further 
development of a vision
• Consider who are the main stakeholders 
to adopt and develop the vision
• Spend time thinking of how to generate 
motivation from within
o ‘Inevitability’, as a driver for change, needs to 
be handled carefully
oAppeal to scientists’ basic instinct: they just 
want to play!
o Remember most pathology managers are still 
scientists
• Prepare to observe and guide their 
strengths (Goleman leadership styles)
• Provide the framework and environment 
for discussions
• Ensure ownership of the project by the 
group is understood
 
Plan of Action
• Agreement from Path Gen Manager about 
group leadership
• Identify and contact likely stakeholders in 
Pathology (managers & scientists)
• Set up round table group meetings with 
these key individuals
• Identify common areas of current working
• Explore sharing of current equipment
• Build on medium-term goal of a unified 
molecular laboratory
• Visit institutions that have already 
integrated molecular services
•Decide where we want to be on the 
adoption diffusion curve
 
Progress to date
Two major meetings:
1. First meeting: introduction of group 
members.
o Remit of group set: to explore the options for 
a unified molecular lab
o Terms of reference agreed
o Important statement of faith from Path Gen 
Manager that solution belongs to the group.
2. Second meeting: presentations from 
group members of their departmental 
work & interests, then discussion. Three 
work packages were identified from this 
meeting:
o Local collaboration needed immediately to 
support a particular service at risk
o Working towards a rationalised common 
molecular laboratory 
o Consider options for adopting next-generation 
sequencing
3. Now scheduled:
o Visit to GOSH molecular facility
o Expert CBRC speaker from UCL Genomics
o Next-gen sequencing equipment on loan
 
THE APPROACH
We cannot wait for the average of 11 years from a good idea to its widespread implementation in the NHS*. 
Need to consider collaborative working: the NHS funds translational research, which includes next-generation 
sequencing to build human disease signatures, plus the design & implementation of point-of-care tests. 
Aligning the UCLH vision with a Comprehensive Biomedical Research Centre will form a complementary link.
*Wanless; NHS review 2002
